Actas de congresos
Incretins: Clinical Physiology And Bariatric Surgery - Correlating The Entero-endocrine System And A Potentially Anti-dysmetabolic Procedure
Registro en:
Obesity Surgery. , v. 17, n. 5, p. 569 - 576, 2007.
9608923
10.1007/s11695-007-9098-y
2-s2.0-34250617485
Autor
Lamounier R.N.
Pareja J.C.
Tambascia M.A.
Geloneze B.
Institución
Resumen
The digestive tract is well known for its endocrine functions. Recently, many studies have been reinforcing its role as a therapeutic target for both diabetes and obesity. Losing weight is clinically very difficult for most obese patients and the reason for this could be the effect of the physiological adipostatic system that triggers central nervous stimuli to compensate for variations in food intake and in physical activity. Gut hormones seem to have a key role in this complex, regulating body weight and satiety and contributing to glucose homeostasis. The enteroinsular axis appears to be impaired in both obese and diabetic patients. Recent data on bariatric surgery shows its striking effects on glucose control soon after the procedure, before a significant weight loss is achieved. The procedure appears to work beyond anti-obesity having a key metabolic impact possibly sharing a common mechanism with the new class of agents to treat type 2 diabetes mellitus: the incretin mimetics.This symposium discussed new data on the upcoming perspectives on both the pharmacological and the surgical approach to diabetes and obesity. © 2007 Springer Science + Business Media B.V. 17 5 569 576 Meier, J.J., Nauck, M.A., Schmidt, W.E., Gastric inhibitory polypeptide: The neglected incretin revisited (2002) Regul Pept, 107, pp. 1-13 Creutzfeldt, W., Entero-insular axis and diabetes mellitus (1992) Horm Metab Res Suppl, 26, pp. 13-18 Gutniak, M., Orskov, C., Holst, J.J., Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus (1992) N Engl J Med, 326, pp. 1316-1322 Meier, J.J., Hucking, K., Holst, J.J., Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes (2001) Diabetes, 50, pp. 2404-2497 Meier, J.J., Gallwitz, B., Salmen, S., Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes (2003) J Clin Endocrinol Metab, 88, pp. 2719-2725 Patriti, A., Facchiano, E., Sanna, A., The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery (2004) Obes Surg, 14, pp. 840-848 Powley, T.L., Phillips, R.J., Gastric satiation is volumetric, intestinal satiation is nutritive (2004) Physiol Behav, 82, pp. 69-74 Cummings, D.E., Purnell, J.Q., Frayo, R., A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans (2001) Diabetes, 50, pp. 1714-1719 Mundinger, T.O., Cummings, D.E., Taborsky Jr., G.J., Direct stimulation of ghrelin secretion by sympathetic nerves (2006) Endocrinology, 147, pp. 2893-2901 Cummings, D.E., Clement, K., Purnell, J.Q., Elevated plasma ghrelin levels in Prader-Willi syndrome (2002) Nat Med, 8, pp. 643-644 Xu, G., Kaneto, H., Lopez-Avalos, M.D., GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts (2006) Diab Res Clin Pract, 73, pp. 107-110 Service, G.J., Thompson, G.B., Service, F.J., Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery (2005) N Engl J Med, 353, pp. 249-254 Fung, M., Thompson, D., Shapiro, R.J., Effect of glucagonlike peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes (2006) Diab Res Clin Pract, 74, pp. 189-193 Drucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides (2002) Gastroenteroloy, 122, pp. 531-544 Gautier, J.F., Fetita, S., Sobngwi, E., Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes (2005) Diab Metab, 31, pp. 233-242 Munzberg, H., Myers Jr., M.G., Molecular and anatomical determinants of central leptin resistance (2005) Nat Neurosci, 8, pp. 566-570 De Souza, C.T., Araujo, E.P., Bordin, S., Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus (2005) Endocrinology, 146, pp. 4192-4199 Turton, M.D., O'Shea, D., Gunn, I., A role for glucagonlike peptide-1 in the central regulation of feeding (1996) Nature, 379, pp. 69-72 Hansotia, T., Baggio, L.L., Delmeire, D., Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors (2004) Diabetes, 53, pp. 1326-1335 Yamamoto, H., Lee, C.E., Marcus, J.N., Glucagon-like peptide- 1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons (2002) J Clin Invest, 110, pp. 43-52 Nystrom, T., Gutniak, M.K., Zhang, Q., Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease (2004) Am J Physiol Endocrinol Metab, 287, pp. 1209-E1215 Nikolaidis, L.A., Elahi, D., Hentosz, T., Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy (2004) Circulation, 110, pp. 955-961 Nikolaidis, L.A., Mankad, S., Sokos, G.G., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion (2004) Circulation, 109, pp. 962-965 Yu, M., Moreno, C., Hoagland, K.M., Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats (2003) J Hypertens, 21, pp. 1125-1135 Meier, J.J., Gallwitz, B., Askenas, M., Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes (2005) Diabetologia, 48, pp. 1872-1881 Nyholm, B., Walker, M., Gravholt, C.H., Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: Evidence of several aberrations (1999) Diabetologia, 42, pp. 1314-1323 Schou, J.H., Pilgaard, K., Vilsbøll, T., Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight (2005) J Clin Endocrinol Metab, 90, pp. 4912-4919 Anini, Y., Brubaker, P.L., Role of leptin in the regulation of glucagon-like peptide-1 secretion (2003) Diabetes, 52, pp. 252-259 Vilsbøll, T., Knop, F.K., Krarup, T., The pathophysiology of diabetes involves a defective amplification of the latephase insulin response to glucose by glucose-dependent insulinotropic polypeptide - Regardless of etiology and phenotype (2003) J Clin Endocrinol Metab, 88, pp. 4803-4897 Lugari, R., Dei Cas, A., Ugolotti, D., Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion (2004) Horm Metab Res, 36, pp. 111-115 Ryskjaer, J., Deacon, C.F., Carr, R.D., Plasma dipeptidyl peptidase- IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake (2006) Eur J Endocrinol, 155, pp. 485-493 Green, B.D., Irwin, N., Duffy, N.A., Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (2006) Eur J Pharmacol, 547, pp. 192-199 Defronzo, R.A., Ratner, R.E., Han, J., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes (2005) Diabetes Care, 28, pp. 1092-1100 Buse, J.B., Henry, R.R., Han, J., Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea- treated patients with type 2 diabetes (2004) Diabetes Care, 27, pp. 2628-2635 Kendall, D.M., Riddle, M.C., Rosenstock, J., Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea (2005) Diabetes Care, 28, pp. 1083-1091 Heine, R.J., Van Gaal, L.F., Johns, D., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial (2005) Ann Intern Med, 143, pp. 559-569 Madsbad, S., Schmitz, O., Ranstam, J., Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12- week, double-blind, randomized, controlled trial (2004) Diabetes Care, 27, pp. 1335-1342 Barnett, A., DPP-4 inhibitors and their potential role in the management of type 2 diabetes (2006) Int J Clin Pract, 60, pp. 1454-1470 Nielsen, L.L., Young, A.A., Parkes, D.G., Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes (2004) Regul Pept, 117, pp. 77-88 Fineman, M.S., Bicsak, T.A., Shen, L.Z., Effect on glycemic control of exenatide (synthetic Exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes (2003) Diabetes Care, 26, pp. 2370-2377 Kolterman, O.G., Buse, J.B., Fineman, M.S., Synthetic Exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes (2003) J Clin Endocrinol Metab, 88, pp. 3082-3089 Fehse, F., Trautmann, M., Holst, J.J., Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes (2005) J Clin Endocrinol Metab, 90, pp. 5991-5997 Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas (2000) Diabetes, 49, pp. 741-748 Herman, G.A., Bergman, A., Stevens, C., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes (2006) J Clin Endocrinol Metab, 91, pp. 4612-4619 Nauck, M.A., Meininger, G., Sheng, D., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial (2007) Diab Obes Metab, 9, pp. 194-205 Rosenstock, J., Brazg, R., Andryuk, P.J., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (2006) Clin Ther, 28, pp. 1556-1568 Rosenstock, J., Baron, M.A., Dejager, S., Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes (2007) Diabetes Care, 30, pp. 217-223 Mari, A., Sallas, W.M., He, Y.L., Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes (2005) J Clin Endocrinol Metab, 90, pp. 4888-4894 Ahrén, B.O., Landin-Olsson, M., Jansson, P.A., Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes (2004) J Clin Endocrinol Metab, 89, pp. 2078-2084 Sjöström, L., Lindroos, A.K., Peltonen, M., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery (2004) N Engl J Med, 351, pp. 2683-2693 Cummings, D.E., Weigle, D.S., Frayo, R.S., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery (2002) N Engl J Med, 346, pp. 1623-1630 Geloneze, B., Tambascia, M.A., Pilla, V.F., Ghrelin: A gutbrain hormone: Effect of gastric bypass surgery (2003) Obes Surg, 13, pp. 17-22 Fruhbeck, G., Rotellar, F., Hernandez-Lizoain, J.L., Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia (2004) Obes Surg, 14, pp. 1208-1215 Stoeckli, R., Chanda, R., Langer, I., Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass (2004) Obes Res, 12, pp. 346-350 Korner, J., Bessler, M., Cirilo, L.J., Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin (2005) J Clin Endocrinol Metab, 90, pp. 359-365 Morínigo, R., Moizé, V., Musri, M., Glucagon-like peptide- 1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects (2006) J Clin Endocrinol Metab, 91, pp. 1735-1740 Marinari, G.M., Papadia, F.S., Briatore, L., Type 2 diabetes and weight loss following biliopancreatic diversion for obesity (2006) Obes Surg, 16, pp. 1440-1445 Guidone, C., Manco, M., Valera-Mora, E., Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery (2006) Diabetes, 55, pp. 2025-2031 Strader, A.D., Vahl, T.P., Jandacek, R.J., Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats (2005) Am J Physiol Endocrinol Metab, 288, pp. 447-E453 Rubino, F., Forgione, A., Cummings, D.E., The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes (2006) Ann Surg, 244, pp. 741-749 Gumbs, A.A., Modlin, I.M., Ballantyne, G.H., Changes in insulin resistance following bariatric surgery: Role of caloric restriction and weight loss (2005) Obes Surg, 15, pp. 462-473 Ballantyne, G.H., Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery (2006) Obes Surg, 16, pp. 703-795 Ballantyne, G.H., Farkas, D., Laker, S., Short-term changes in insulin resistance following weight loss surgery for morbid obesity: Laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass (2006) Obes Surg, 16, pp. 1189-1197 Pitombo, C., Araujo, E.P., De Souza, C.T., Amelioration of diet-induced diabetes mellitus by removal of visceral fat (2006) J Endocrinol, 191, pp. 699-706 Thörne, A., Lönnqvist, F., Apelman, J., A pilot study of long-term effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding (2002) Int J Obes, 26, pp. 193-199 De Paula, A.L., MacEdo, A.L., Prudente, A.S., Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")-pilot study of a new operation (2006) Surg Obes Relat Dis, 2, pp. 464-467